Market Overview:

The global drug-eluting stents market size reached US$ 7.8 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 11.4 Billion by 2028, exhibiting a growth rate (CAGR) of 6.31% during 2023-2028.

A drug-eluting stent (DES) is a coronary device that is used for the slow release of drugs in peripheral or coronary arteries to block cell proliferation and promote a healthy flow of blood. It consists of a metallic stent, polymer coating and anti-restenosis drug. The stent is coated with medications that assist the arteries to remain smooth and ensure adequate blood flow. DES is widely used to treat blockages in heart arteries, prevent plaque buildup, blood clots and reduce repeated revascularization. The stent is minimally invasive (MI) and offers lower restenosis rates, enhanced vessel healing and reduced need for prolonged dual antiplatelet therapy.

Drug-Eluting Stents Market Trends:

The rising geriatric population prone to chronic medical ailments is one of the key factors driving the growth of the market. DES is widely utilized in patients with a high risk of developing arterial disorders as the stents aid in reducing the need for invasive procedures, such as coronary artery bypass surgeries. Additionally, the increasing prevalence of cardiovascular diseases due to the unhealthy dietary patterns, lack of physical activity and sedentary lifestyles of the masses is favoring the market growth. Moreover, various technological advancements, such as the launch of bioresorbable stents, are providing a thrust to the market growth. These stents are easily dissolvable in the body and reduce the risk of developing stent thrombosis. In line with this, the widespread adoption of stents with polymer-free coatings is positively impacting the market growth. These stents exhibit a higher drug loading capacity and quicker drug-eluting rate. Other factors, including the rising incidence of abnormal heart rhythms, heart failure and heart attack disease, along with the increasing demand for MI techniques among the masses, are anticipated to drive the market toward growth.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global drug-eluting stents market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on coating, drug, stent platform, generation, application and end user.

Breakup by Coating:

• Polymer Based Coating
• Polymer Free Coating
   

Breakup by Drug:

• Sirolimus
• Paclitaxel
• Zotarolimus
• Everolimus
• Biolimus
• Others
   

Breakup by Stent Platform:

• Stainless-steel
• Cobalt-Chromium
• Platinum-Chromium
• Nitinol
• Others
   

Breakup by Generation:

• 1st Generation
• 2nd Generation
• 3rd Generation
• 4th Generation
   

Breakup by Application:

• Coronary Artery Disease
• Peripheral Artery Disease
   

Breakup by End User:

• Hospitals
• Ambulatory Surgical Centers
• Others
   

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa
   

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, B. Braun Melsungen AG, Biosensors International Group Ltd., Biotronik, Boston Scientific Corporation, Cardinal Health Inc., Cook Medical LLC (Cook Group Incorporated), Lepu Medical Technology (Beijing) Co. Ltd., Medtronic plc, MicroPort Scientific Corporation, Sino Medical Sciences Technology Inc. and Terumo Corporation.

Report Coverage: